Javascript must be enabled to continue!
Dementia with Lewy bodies and Parkinson’s disease dementia
View through CrossRef
Dementia with Lewy bodies and Parkinson’s disease dementia belong to the α-synucleinopathies, a family of diseases pathologically characterized by aggregation of α-synuclein in Lewy bodies in the brain. In this chapter we present the epidemiological data for both conditions including new data on MCI. Clinical diagnostic criteria are reviewed and the different neuropathology staging systems for DLB and PDD and the most important genetic findings are considered. Biomarkers in DLB and PDD with particular focus on imaging techniques like CIT-SPECT and MRI are described. Important clinical symptoms in both conditions are presented in detail and the most important clinical differential diagnoses are discussed. Pharmacological and non- pharmacological treatment of different symptoms in both conditions are discussed with particular emphasis on the choline esterase inhibitors and antipsychotic medications.New data on memantine are presented.
Title: Dementia with Lewy bodies and Parkinson’s disease dementia
Description:
Dementia with Lewy bodies and Parkinson’s disease dementia belong to the α-synucleinopathies, a family of diseases pathologically characterized by aggregation of α-synuclein in Lewy bodies in the brain.
In this chapter we present the epidemiological data for both conditions including new data on MCI.
Clinical diagnostic criteria are reviewed and the different neuropathology staging systems for DLB and PDD and the most important genetic findings are considered.
Biomarkers in DLB and PDD with particular focus on imaging techniques like CIT-SPECT and MRI are described.
Important clinical symptoms in both conditions are presented in detail and the most important clinical differential diagnoses are discussed.
Pharmacological and non- pharmacological treatment of different symptoms in both conditions are discussed with particular emphasis on the choline esterase inhibitors and antipsychotic medications.
New data on memantine are presented.
Related Results
Diagnosis and Therapy for Lewy Body Dementia
Diagnosis and Therapy for Lewy Body Dementia
Almost undistinguished some 30 years ago, dementia with Lewy bodies is now shown to be the second most common neurodegenerative cause of dementia in the elderly. A host of neuroinf...
“I See Them Sitting on My Bed, Doctor”
“I See Them Sitting on My Bed, Doctor”
Many movement disorders specialists would consider dementia with Lewy bodies to be on one end of a spectrum of presentations associated with Lewy body pathology. Parkinson’s diseas...
Pathogenesis of Lewy Body Dementia
Pathogenesis of Lewy Body Dementia
This chapter discusses the Pathogenesis of Lew Body Dementia. The Lewy body dementias (LBDs) are a spectrum of dementing neurodegenerative disorders underpinned by the pathological...
Dementia 1: Defining Dementia, Alzheimer’s Disease and Frontotemporal Dementia (DRAFT)
Dementia 1: Defining Dementia, Alzheimer’s Disease and Frontotemporal Dementia (DRAFT)
The video in this chapter explores dementia, and focuses on definitions of dementia, Alzheimer’s disease and Frontotemporal Dementia. Dementia is defined as a cognitive decline in ...
Genetics of Neurodegenerative Diseases
Genetics of Neurodegenerative Diseases
A great deal has been discovered about Neurodegenerative disorders (NDDs) including Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, dementia with Lewy bodies . T...
Molecular genetics and biology of dementia
Molecular genetics and biology of dementia
Considerable progress has been made in our understanding of the genetics and molecular biology of dementia. In this chapter we focus predominantly on the most common form of dement...
Neurodegenerative Diseases
Neurodegenerative Diseases
With an increasingly aging population, neurodegenerative diseases-such as Alzheimer’s disease, Lewy body dementia, frontotemporal dementia, and Parkinson’s disease-are becoming mor...

